Sarepta recent weakness brings buying opportunity, says JPMorgan
JPMorgan sees a long-term buying opportunity after Sarepta (SRPT) shares were under pressure last week post earnings. Near-term, if one ...
The Pharma Letter2h
Sarepta halts development of Duchenne drug as Elevidys soars
Sarepta Therapeutics (Nasdaq: SRPT) has announced it will cease development of SRP-5051, an experimental drug for Duchenne ...
Dr Anthony Filippis to helm Neurotech as it advances its NTI164 strategy in 2025
Neurotech has appointed Dr Anthony Filippis as its managing director to steer the company as it progresses clinical testing ...
CairoScene.com12h
Rare Genetic Disorder Identified in Saudi Arabia for First Time
Saudi researchers from Qassim University identified Bethlem Myopathy, a rare genetic disorder. The scientific discovery sheds ...
Business Insider16h
Avidity Biosciences’ Clinical Advancements Positioning for Regulatory Success
including myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), and Duchenne muscular dystrophy (DMD). In DM1, Avidity Biosciences continues to progress with their Phase 3 ...